Exelixis

Natera

Corcept Therapeutics

Intra-Cellular Therapies

ACADIA Pharma

Incyte

Catalyst Pharmaceuticals

Gilead Sciences

Neurocrine Biosciences

United Therapeutics

First Trust NYSE Arca Biotechnology Index Fund

FBT tracks an equal-weighted index of US biotechnology stocks.

The First Trust NYSE Arca Biotechnology ETF (FBT) was launched on 06/19/2006, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed exchange traded fund launched on 06/19/2006.

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

Biotech stocks have not regained their 2021 peak levels, making them a potential catch-up trade. First Trust NYSE Arca Biotechnology Index Fund ETF is a fund that replicates the performance of the NYSE Arca Biotechnology Index. The FBT ETF invests equally in 30 leading biotech companies, offering exposure to the sector's growth potential with diversification.

FBT: An Equal Weight Way To Play Biotech

iShares Core U.S. Aggregate Bond ETF

ARK Fintech Innovation ETF

ARK Innovation ETF

ARK Web x.0 ETF

ProShares Bitcoin Strategy ETF

Bitwise Crypto Innovators ETF

Global X Blockchain & Bitcoin Strategy ETF

2x Bitcoin Strategy ETF

Global X Blockchain ETF

Valkyrie Bitcoin Strategy ETF

First Trust SkyBridge Crypto Industry and Digital Economy ETF

VanEck Vectors Digital Transformation ETF

Invesco DB Agriculture Fund

Xtrackers MSCI EAFE Hedged Equity ETF

Hashdex Bitcoin ETF

Fidelity Covington Trust-Fidelity Crypto Industry And Digital Payments Etf

First Trust Global Tactical Commodity Strategy Fund

Grayscale Future of Finance ETF

iShares Blockchain And Tech ETF

iShares Transportation Average ETF

JPMorgan Equity Premium Income ETF

US Global Jets ETF

KraneShares Global Carbon ETF

Simplify Bitcoin Strategy PLUS Income ETF

Hello! This week's ETF Wrap looks at top performers in the first half of 2023, as well as flows, as stocks rally and crypto-related funds jump so far this year.

Here are the top-performing ETFs in first half of 2023 as crypto-related funds soar

Most stocks in FBT's biotechnology portfolio beat returns of S&P 500 during the past one year. FBT also registered a price growth of 15.5 percent. However, over the past five months, return has been much lower than S&P 500, and price growth of FBT's portfolio has largely been disappointing. There is a likelihood of this price falling further down to cross the 52-week low. This assumption gets further validation through moving average indicators.

FBT: No Great Prospects Despite Huge Price Gain Over Past One Year

Agios Pharmaceuticals

Amgen

ARK Genomic Revolution Multi-Sector ETF

VanEck Vectors Biotech ETF

BioMarin Pharmaceutical

CareDx

Exact Sciences

FibroGen

iShares Nasdaq Biotechnology ETF

Ionis Pharma

IQVIA Hlds

Madrigal Pharmaceuticals

Moderna

Pacific Biosciences of California

Regeneron Pharmaceuticals

Seagen

Teladoc

TG Therapeutics

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

Here are the five best biotech ETFs to invest in right now.

Investing in Biotech ETFs

Virtus LifeSci Biotech Clinical Trials ETF

iShares U.S. Pharmaceuticals ETF

iShares U.S. Healthcare Providers ETF

iShares U.S. Medical Devices ETF

iShares U.S. Healthcare ETF

Invesco Dynamic Biotechnology & Genome ETF

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

Invesco S&P 500 Equal Weight Health Care ETF

Vanguard Health Care ETF

Health Care Select Sector SPDR Fund

SPDR S&P Pharmaceuticals ETF

How SVB's collapse is impacting healthcare startups. Pfizer to buy Seagen for $43B.

The Fall Of SVB: What It Means For Healthcare Startups

Virtus LifeSci Biotech Products ETF

Rising rate worries have weighed on the biotech sector. However, these biotech ETFs still have lost the least in recent days.

5 Least-Hurt Biotech ETFs of the Last Week

This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?

Biotech ETF (FBT) Hits New 52-Week High

Global X Longevity Thematic ETF 

BlackRock Future Health ETF

Principal Healthcare Innovators Index ETF

Loncar Cancer Immunotherapy ETF

Global X Telemedicine & Digital Health ETF

Fidelity MSCI Health Care ETF

First Trust Nasdaq Pharmaceuticals ETF 

First Trust Health Care AlphaDEX Fund

Amplify Treatments Testing & Advancements ETF

Global X Genomics & Biotechnology ETF

 Franklin Genomic Advancements ETF

ROBO Global Healthcare Technology and Innovation ETF

Invesco Nasdaq Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

iShares Global Healthcare ETF

Eli Lilly

Global X Longevity Thematic ETF

First Trust Indxx Medical Devices ETF

Merck

Novo Nordisk

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Simplify Health Care ETF

Invesco S&P SmallCap Health Care ETF

Invesco DWA Healthcare Momentum ETF

ALPS Medical Breakthroughs ETF

Wisdomtree BioRevolution Fund

SPDR S&P Health Care Equipment ETF

SPDR S&P Health Care Services ETF

How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.

Can Health Care Stocks Outperform Again In 2023?

Fidelity MSCI Materials Index ETF

iShares U.S. Industrials ETF

Vanguard Energy ETF

SPDR S&P Oil & Gas Equipment & Services ETF

Materials Select Sector SPDR Fund

Industrial Select Sector SPDR Fund

These four top-ranked sector ETFs topped the market in the ongoing fourth quarter.

4 Market-Beating Top Sector ETFs of Q4 to Buy Now

Invesco Dynamic Media ETF

PBS and FBT saw massive trading volumes in Monday trading session.

Media and Biotech: 2 ETFs to Watch for Outsized Volume

ProShares Ultra Nasdaq Biotechnology

iShares Neuroscience And Healthcare ETF

Recognition that aging populations will give rise to new healthcare needs and heightened awareness of mental health issues are bringing renewed focus to neurological health. Recent advances in genomics and immunology, new diagnostics and surgeries, and reductions in stigma associated with mental health are unlocking radical progress in neuroscience this decade akin to the genomics revolution of the past two decades.

Why Now Could Be The Time To Consider Neuroscience Investments

FBT doesn't pay any dividend and had a negative price growth over the short term. Barring the inverse funds, all other biotechnology ETFs had a high negative growth over the past 12 months.

FBT: This Biotech ETF Is Better Avoided In The Short Term

FBT is a passive biotechnology ETF, which doesn't pay any dividend. Baring the past one year, FBT's price return has outperformed the S&P 500.

FBT: A Long Term Hold If Done With Effective Hedging

Johnson & Johnson

Pfizer

Biotech ETFs was the biggest gainer last week.

Biotech ETFs That Outperformed Last Week

Wall Street was downbeat last week with all indexes in the red. Still, Healthcare sector emerged as a key winner last week.

Healthcare Emerges as Best Sector of Last Week: 5 Top ETFs

In an effort to combat the coronavirus outbreak and accelerate the distribution process of extra doses in the United States, the FDA has approved the vaccine booster shots.

Can Biotech ETFs Gain From Positive Booster Update?

The U.S. government's plans to make COVID-19 vaccine booster shots available from next month will likely increase the profits of vaccine makers.

Biotech ETFs to Benefit From Latest Booster Update

The biotech sector seems like a lucrative investment space as the delta variant of coronavirus continues to spread.

Delta Variant Surge Brings Biotech ETFs in Focus

Biogen

Clover Health Investments

Orphazyme A/S

Investors may want to tap the bullishness in the sector with the best biotech ETFs of last week.

Top-Performing Biotech ETFs of Last Week

Annovis Bio

Arvinas Inc

Anavex Life Sciences

Biohaven Pharmaceutical Hld

Denali Therapeutics

abrdn Life Sciences Investors 

Defiance Nasdaq Junior Biotechnology ETF

INmune Bio Inc

Karuna Therapeutics Inc

Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

Prothena

Cassava Sciences Inc

Supernus Pharmaceuticals

Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotech sector.

Biotechs Ready To Roar

Biotech investors may have reason to celebrate this week, as the FDA approved Biogen's Alzheimer's disease drug Aducanumab on Monday, ushering in the first medication to be allowed by U.S. regulators to help the mental deterioration seen in people living with Alzheimer's. The drug is also the first new medicine for the disease in nearly [.

Will Biotech ETFs Benefit from Biogen's New Alzheimer's Drug?

Invesco Buyback Achievers ETF

For the first time in 18 years, there was a new treatment for Alzheimer's Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that can reduce the clinical decline of dementia.

5 Top ETFs With Exposure To Biogen

The Biden administration recently informed about supporting the waiver of intellectual property protections for COVID-19 vaccines that has been proposed by South Africa and India.

Biotech ETFs to Suffer as US Backs IP Waiver for COVID-19 Vaccines

News for First Trust NYSE Arca Biotechnology Index Fund ETF (FBT)